Lisa Willmon Lpc-s Pllc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 356 Nink Rd, Smithville, TX 78957 Phone: 512-333-4040 |
River City Specialty Care Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1509 Dorothy Nichols Ln Unit B, Smithville, TX 78957 Phone: 512-581-2921 |
News Archive
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.
A recent Kansas State University study found that the availability of supermarkets - rather than the lack of them -increased the risk of obesity for low-income women living in small cities. This suggests that policies to increase healthful eating behaviors might need to be tailored based on geographic location.
Earlier studies have pegged the risk of motor vehicle crashes with teenagers suffering from attention-deficit hyperactivity disorder (ADHD) behind the wheel, as much higher than what a recent study has revealed. Now it is known that the risk of a motor vehicle crashes with adolescents with ADHD is 36% higher than all other newly licensed teenagers and young drivers. This is high but earlier the risk was considered to be four times higher than this.
Despite criticism from the state insurance commissioner and several statewide consumer groups, Aetna said Thursday it's going ahead with a recent hike in health care premiums for small businesses. Aetna's new increases, which average 8 percent annually and took effect April 1, were deemed "unreasonable" this week by state Department of Insurance Commissioner David Jones.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
› Verified 9 days ago